Singapore markets closed

GSK plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1,676.00+6.00 (+0.36%)
As of 03:22PM BST. Market open.
Full screen
Previous close1,670.00
Open1,643.00
Bid1,675.50 x 0
Ask1,676.00 x 0
Day's range1,643.00 - 1,679.50
52-week range1,302.60 - 1,725.81
Volume1,925,600
Avg. volume8,764,554
Market cap68.482B
Beta (5Y monthly)0.27
PE ratio (TTM)13.97
EPS (TTM)1.20
Earnings date01 May 2024
Forward dividend & yield0.64 (3.83%)
Ex-dividend date22 Feb 2024
1y target estN/A
  • Insider Monkey

    20 Fastest Growing Health Tech Companies in the World

    In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]

  • Reuters

    UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

  • Reuters

    GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    (Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.